vfend®tdm calculation tool (Pfizer Inc)
90
Structured Review
Pfizer Inc
vfend®tdm calculation tool
Vfend®Tdm Calculation Tool, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vfend%C2%AEtdm+calculation+tool/vfend+tdm+calculation+tool/pm40414726-32-101-104
Average 90 stars, based on 1 article reviews
Vfend®Tdm Calculation Tool, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vfend%C2%AEtdm+calculation+tool/vfend+tdm+calculation+tool/pm40414726-32-101-104
Average 90 stars, based on 1 article reviews
vfend®tdm calculation tool - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Clinical Proteomics:Article Title: Effectiveness and safety of the simulation-based first-dose design of voriconazole. Article Snippet: Background: We investigated whether the initial voriconazole (VRCZ) dosing design, as determined using simulation software with a population pharmacokinetic model of Japanese patients, impacts the effectiveness and safety when compared with VRCZ initiation according to the package insert.. Methods: In this single-center retrospective observational study, we employed records from Tosei General Hospital (a 633-bed hospital), dated April 2017 to September 2023.. Eligible patients were divided into the softwarebased simulation group, comprising patients administered initial VRCZ dosage adjustment by pharmacists using software-based simulation, and the standard therapy group, whose dosage was administered by a physician following the package insert recommendations without simulation. Article Title: Prospective Analysis of Factors Influencing Inter-Individual Variation in Trough Plasma Voriconazole Concentrations in Older Patients-Impact of High α1-Acid Glycoprotein Levels. Article Snippet: Due to the existence of genetic polymorphisms in CYP2C19, a major metabolizing enzyme for VRCZ, it has been reported that poor metabolizers (PMs) with defective or reduced metabolic capacity due to genetic polymorphisms have a slower rate of VRCZ metabolism, resulting in abnormally high plasma concentrations, which is one of the major determinants of toxicity.8) The frequency of PM is relatively higher in Asians9); a genetic analysis of Software:Article Title: Effectiveness and safety of the simulation-based first-dose design of voriconazole. Article Snippet: Background: We investigated whether the initial voriconazole (VRCZ) dosing design, as determined using simulation software with a population pharmacokinetic model of Japanese patients, impacts the effectiveness and safety when compared with VRCZ initiation according to the package insert.. Methods: In this single-center retrospective observational study, we employed records from Tosei General Hospital (a 633-bed hospital), dated April 2017 to September 2023.. Eligible patients were divided into the softwarebased simulation group, comprising patients administered initial VRCZ dosage adjustment by pharmacists using software-based simulation, and the standard therapy group, whose dosage was administered by a physician following the package insert recommendations without simulation. Article Title: Prospective Analysis of Factors Influencing Inter-Individual Variation in Trough Plasma Voriconazole Concentrations in Older Patients-Impact of High α1-Acid Glycoprotein Levels. Article Snippet: Due to the existence of genetic polymorphisms in CYP2C19, a major metabolizing enzyme for VRCZ, it has been reported that poor metabolizers (PMs) with defective or reduced metabolic capacity due to genetic polymorphisms have a slower rate of VRCZ metabolism, resulting in abnormally high plasma concentrations, which is one of the major determinants of toxicity.8) The frequency of PM is relatively higher in Asians9); a genetic analysis of Drug discovery:Article Title: Effectiveness and safety of the simulation-based first-dose design of voriconazole. Article Snippet: Background: We investigated whether the initial voriconazole (VRCZ) dosing design, as determined using simulation software with a population pharmacokinetic model of Japanese patients, impacts the effectiveness and safety when compared with VRCZ initiation according to the package insert.. Methods: In this single-center retrospective observational study, we employed records from Tosei General Hospital (a 633-bed hospital), dated April 2017 to September 2023.. Eligible patients were divided into the softwarebased simulation group, comprising patients administered initial VRCZ dosage adjustment by pharmacists using software-based simulation, and the standard therapy group, whose dosage was administered by a physician following the package insert recommendations without simulation. Article Title: Prospective Analysis of Factors Influencing Inter-Individual Variation in Trough Plasma Voriconazole Concentrations in Older Patients-Impact of High α1-Acid Glycoprotein Levels. Article Snippet: Due to the existence of genetic polymorphisms in CYP2C19, a major metabolizing enzyme for VRCZ, it has been reported that poor metabolizers (PMs) with defective or reduced metabolic capacity due to genetic polymorphisms have a slower rate of VRCZ metabolism, resulting in abnormally high plasma concentrations, which is one of the major determinants of toxicity.8) The frequency of PM is relatively higher in Asians9); a genetic analysis of |